Orchestra BioMed Holdings, Inc. (OBIO) has a negative trailing P/E of -3.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 13.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -32.37%, forward earnings yield 7.22%.
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2020 | -12.3 | 0.00 | -5.40 | 45.93 | - |
| 2021 | -9.0 | -0.08 | -2.89 | -263.60 | - |
| 2022 | -7.6 | 0.00 | 4.84 | 71.95 | - |
| 2023 | -6.2 | -0.51 | 4.46 | 109.91 | - |
| 2024 | -2.4 | -0.20 | 4.47 | 55.83 | - |
| 2025 | -3,008.8 | 90.81 | 2,513.96 | 4,758.67 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2020 | $-1.04 | $5.7M | $-21.36M | -374.5% |
| 2021 | $-1.13 | $-782K | $-23.01M | - |
| 2022 | $-2.24 | $3.53M | $-33.61M | -951.3% |
| 2023 | $-1.48 | $2.76M | $-49.12M | -1779.7% |
| 2024 | $-1.66 | $2.64M | $-61.02M | -2313.3% |
| 2025 | $-1.11 | $33.48M | $-52.96M | -158.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.77 | $-1.98 – $-1.61 | $1.68M | $351.7K – $5.56M | 6 |
| 2027 | $-1.57 | $-1.60 – $-1.53 | $897.25K | $488.77K – $1.98M | 3 |
| 2028 | $-1.02 | $-1.32 – $-0.62 | $14.88M | $8.11M – $32.77M | 3 |
| 2029 | $-0.31 | $-0.79 – $-0.13 | $53.64M | $29.22M – $118.09M | 1 |
| 2030 | $0.33 | $0.13 – $0.85 | $111.31M | $60.63M – $245.03M | 1 |
